Potential Therapeutic Target Via Passive Immunization 2

[1]  Tami D. Lieberman,et al.  Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection. , 2012, The Journal of infectious diseases.

[2]  C. V. van Dolleweerd,et al.  Passive immunity in the prevention of rabies. , 2012, The Lancet. Infectious diseases.

[3]  Donoghue,et al.  Acinetobacter baumannii , 2012, Virulence.

[4]  J. Vila,et al.  The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace , 2012, Front. Microbio..

[5]  M. Adams,et al.  Active and Passive Immunization Protects against Lethal, Extreme Drug Resistant-Acinetobacter baumannii Infection , 2012, PloS one.

[6]  N. Safdar,et al.  Polyclonal Immunoglobulins and Hyperimmune Globulins in Prevention and Management of Infectious Diseases Keywords Ivig Immunoglobulin Sepsis Toxic Shock Cytomegalovirus Viral Hepatitis , 2022 .

[7]  M. P. van der Linden,et al.  Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe , 2011, Expert review of vaccines.

[8]  K. Bryant,et al.  Haemophilus influenzae type b–Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers , 2011, Expert review of vaccines.

[9]  M. Falagas,et al.  Treatment of Acinetobacter infections , 2010 .

[10]  F. Avci,et al.  How bacterial carbohydrates influence the adaptive immune system. , 2010, Annual review of immunology.

[11]  G. Pier,et al.  The pgaABCD Locus of Acinetobacter baumannii Encodes the Production of Poly-β-1-6-N-Acetylglucosamine, Which Is Critical for Biofilm Formation , 2009, Journal of bacteriology.

[12]  T. Umland,et al.  Penicillin-binding protein 7/8 contributes to the survival of Acinetobacter baumannii in vitro and in vivo. , 2009, The Journal of infectious diseases.

[13]  T. Russo,et al.  Capsular polysaccharide and the O-specific antigen impede antibody binding: a potential obstacle for the successful development of an extraintestinal pathogenic Escherichia coli vaccine. , 2009, Vaccine.

[14]  Harald Seifert,et al.  Acinetobacter baumannii: Emergence of a Successful Pathogen , 2008, Clinical Microbiology Reviews.

[15]  R. Bonomo,et al.  Why are we afraid of Acinetobacter baumannii? , 2008, Expert review of anti-infective therapy.

[16]  A. Campagnari,et al.  Identification and Characterization of an Acinetobacter baumannii Biofilm-Associated Protein , 2007, Journal of bacteriology.

[17]  N. Sharon.  Celebrating the golden anniversary of the discovery of bacillosamine, the diamino sugar of a Bacillus. , 2007, Glycobiology.

[18]  R. Bonomo,et al.  Global Challenge of Multidrug-Resistant Acinetobacter baumannii , 2007, Antimicrobial Agents and Chemotherapy.

[19]  T. Russo,et al.  A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate. , 2007, Vaccine.

[20]  M. Falagas,et al.  The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[21]  D. Ecker,et al.  Identification of Acinetobacter Species and Genotyping of Acinetobacter baumannii by Multilocus PCR and Mass Spectrometry , 2006, Journal of Clinical Microbiology.

[22]  P. Fournier,et al.  Nosocomial Infections Caused by Acinetobacter baumannii A Major Threat Worldwide , 2006, Infection Control & Hospital Epidemiology.

[23]  P. Fournier,et al.  The epidemiology and control of Acinetobacter baumannii in health care facilities. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  P. Hoffmeyer,et al.  Atypical Infections in Tsunami Survivors , 2005, Emerging infectious diseases.

[25]  Jonathan R Edwards,et al.  Overview of nosocomial infections caused by gram-negative bacilli. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  D. Rixen,et al.  The long-distance tertiary air transfer and care of tsunami victims: Injury pattern and microbiological and psychological aspects* , 2005, Critical care medicine.

[27]  B. Gibson,et al.  Characterization of a Cluster of Three Glycosyltransferase Enzymes Essential for Moraxella catarrhalis Lipooligosaccharide Assembly , 2005, Journal of bacteriology.

[28]  Jianjun Li,et al.  Structural analysis of the lipopolysaccharide of Pasteurella multocida strain VP161: identification of both Kdo-P and Kdo-Kdo species in the lipopolysaccharide. , 2005, Carbohydrate research.

[29]  R. Hughes,et al.  Guillain-Barré syndrome , 2004, The Lancet.

[30]  O. Holst,et al.  Structural and serological characterisation of the O-antigenic polysaccharide of the lipopolysaccharide from Acinetobacter baumannii strain 24. , 2003, Carbohydrate research.

[31]  A. Troelstra,et al.  Outbreak of a susceptible strain of Acinetobacter species 13 (sensu Tjernberg and Ursing) in an adult neurosurgical intensive care unit. , 2002, The Journal of hospital infection.

[32]  N. Anstey,et al.  Community-Acquired Bacteremic Acinetobacter Pneumonia in Tropical Australia Is Caused by Diverse Strains of Acinetobacter baumannii, with Carriage in the Throat in At-Risk Groups , 2002, Journal of Clinical Microbiology.

[33]  M. Apicella,et al.  The mimicry of human glycolipids and glycosphingolipids by the lipooligosaccharides of pathogenic neisseria and haemophilus. , 2001, Journal of autoimmunity.

[34]  A. Moran,et al.  Review: Lipopolysaccharides in the development of the Guillain-Barré syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies , 2000, Journal of endotoxin research.

[35]  D. Granoff,et al.  Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitidis serogroup B disease. , 1999, FEMS immunology and medical microbiology.

[36]  J. Thomas-Oates,et al.  The structures of the carbohydrate backbones of the lipopolysaccharides from Escherichia coli rough mutants F470 (R1 core type) and F576 (R2 core type). , 1999, European journal of biochemistry.

[37]  A. Campagnari,et al.  Outer membrane protein B1, an iron-repressible protein conserved in the outer membrane of Moraxella (Branhamella) catarrhalis, binds human transferrin , 1996, Infection and immunity.

[38]  M. Frank,et al.  Generation of isogenic K54 capsule‐deficient Escherichia coli strains through TnphoA‐mediated gene disruption , 1993, Molecular microbiology.

[39]  J. Sarwar,et al.  Strain-specific and immunodominant surface epitopes of the P2 porin protein of nontypeable Haemophilus influenzae , 1991, Infection and immunity.

[40]  M. Leinonen,et al.  ANTIGENIC SIMILARITIES BETWEEN BRAIN COMPONENTS AND BACTERIA CAUSING MENINGITIS Implications for Vaccine Development and Pathogenesis , 1983, The Lancet.

[41]  I. Orskov,et al.  Serology, chemistry, and genetics of O and K antigens of Escherichia coli. , 1977, Bacteriological reviews.

[42]  D. Kasper,et al.  Immunologic response of man to group B meningococcal polysaccharide vaccines. , 1972, The Journal of infectious diseases.

[43]  J. Bartlett,et al.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  N. Anstey,et al.  Community-acquired Acinetobacter pneumonia in the Northern Territory of Australia. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  K. Jann,et al.  Structure and biosynthesis of the capsular antigens of Escherichia coli. , 1990, Current topics in microbiology and immunology.